Inhibitory KIR and specific HLA-C gene combinations confer susceptibility to or protection against chronic hepatitis B

Clinical Immunology

Volumn 137, Issue 1, 2010, Pages 139-146

  Gao, Xuejun ^a   Jiao, Yulian ^a   Wang, Laicheng ^a   Liu, Xiaowen ^a   Sun, Wenping ^a   Cui, Bin ^a   Chen, Zijiang ^b   Zhao, Yueran ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Chronic hepatitis B; ; HLA C; ; Human leukocyte antigen; ; Immunity; KIR; ; Natural killer cells;

Indexed keywords

HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LIGAND;

ADOLESCENT; ADULT; AGED; ALLELE; ANTIVIRAL ACTIVITY; ARTICLE; CHILD; CHRONIC DISEASE; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HEPATITIS B; HLA SYSTEM; HOMOZYGOTE; HUMAN; IMMUNITY; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HEPATITIS B, CHRONIC; HETEROZYGOTE; HLA-C ANTIGENS; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, KIR; RECEPTORS, KIR2DL1; RECEPTORS, KIR2DL2; RECEPTORS, KIR2DL3; YOUNG ADULT;

EID: 77956617797     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.05.011     Document Type: Article

References (53)

1. Lee W.M. Hepatitis B virus infection. N. Engl. J. Med. 1997, 337:1733-1745.
2. Lai C.L., Ratziu V., Yuen M.F., Poynard T. Viral hepatitis B. Lancet 2003, 362:2089-2094.
3. Martin M.P., Carrington M. Immunogenetics of viral infections. Curr. Opin. Immunol. 2005, 17:510-516.
4. Thio C.L., Thomas D.L., Karacki P., Gao X., Marti D., Kaslow R.A., Goedert J.J., Hilgartner M., Strathdee S.A., Duggal P., O'Brien S.J., Astemborski J., Carrington M. Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J. Virol. 2003, 77:12083-12087.
5. Thio C.L., Carrington M., Marti D., O'Brien S.J., Vlahov D., Nelson K.E., Astemborski J., Thomas D.L. Class II HLA alleles and hepatitis B virus persistence in African Americans. J. Infect. Dis. 1999, 179:1004-1006.
6. Wu Y.F., Wang L.Y., Lee T.D., Lin H.H., Hu C.T., Cheng M.L., Lo S.Y. HLA phenotypes and outcomes of hepatitis B virus infection in Taiwan. J. Med. Virol. 2004, 72:17-25.
7. Hsu K.C., Chida S., Geraghty D.E., Dupont B. The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol. Rev. 2002, 190:40-52.
8. Vales-Gomez M., Reyburn H., Strominger J. Interaction between the human NK receptors and their ligands. Crit. Rev. Immunol. 2000, 20:223-244.
9. Vivier E., Nunes J.A., Vely F. Natural killer cell signaling pathways. Science 2004, 306:1517-1519.
10. Marsh S.G., Parham P., Dupont B., Geraghty D.E., Trowsdale J., Middleton D., Vilches C., Carrington M., Witt C., Guethlein L.A., Shilling H., Garcia C.A., Hsu K.C., Wain H. Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002. Tissue Antigens 2003, 62:79-86.
11. Vilches C., Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu. Rev. Immunol. 2002, 20:217-251.
12. Hsu K.C., Liu X.R., Selvakumar A., Mickelson E., O'Reilly R.J., Dupont B. Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J. Immunol. 2002, 169:5118-5129.
13. Yawata M., Yawata N., Draghi M., Little A.M., Partheniou F., Parham P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J. Exp. Med. 2006, 203:633-645.
14. Uhrberg M., Valiante N.M., Shum B.P., Shilling H.G., Lienert-Weidenbach K., Corliss B., Tyan D., Lanier L.L., Parham P. Human diversity in killer cell inhibitory receptor genes. Immunity 1997, 7:753-763.
15. Boyington J.C., Sun P.D. A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors. Mol. Immunol. 2002, 38:1007-1021.
16. Deng L., Mariuzza R.A. Structural basis for recognition of MHC and MHC-like ligands by natural killer cell receptors. Semin. Immunol. 2006, 18:159-166.
17. Williams A.P., Bateman A.R., Khakoo S.I. Hanging in the balance: KIR and their role in disease. Mol. Interv. 2005, 5:226-240.
18. Khakoo S.I., Carrington M. KIR and disease: a model system or system of models?. Immunol. Rev. 2006, 214:186-201.
19. Ljunggren H.G., Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol. Today 1990, 11:237-244.
20. Du Z., Gjertson D.W., Reed E.F., Rajalingam R. Receptor-ligand analyses define minimal killer cell Ig-like receptor (KIR) in humans. Immunogenetics 2007, 59:1-15.
21. Nelson G.W., Martin M.P., Gladman D., Wade J., Trowsdale J., Carrington M. Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J. Immunol. 2004, 173:4273-4276.
22. Rajagopalan S., Long E.O. Understanding how combinations of HLA and KIR genes influence disease. J. Exp. Med. 2005, 201:1025-1029.
23. Hiby S.E., Walker J.J., O'Shaughnessy M., Redman K.C.W., Carrington M., Trowsdale J., Moffett A. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J. Exp. Med. 2004, 200:957-965.
24. Boyton R.J., Smith J., Ward R., Jones M., Ozerovitch L., Wilson R., Rose M., Trowsdale J., Altmann D.M. HLA-C and killer cell immunoglobulin-like receptor genes in idiopathic bronchiectasis. Am. J. Respir. Crit. Care Med. 2006, 173:327-333.
25. Naumova E., Mihaylova A., Ivanova M., Mihailova S. Impact of KIR/HLA ligand combinations on immune responses in malignant melanoma. Cancer Immunol. Immunother. 2007, 56:95-100.
26. Romero V., Azocar J., Zuniga J., Clavijo O.P., Terreros D., Gu X., Husain Z., Chung R.T., Amos C., Yunis E.J. Interaction of NK inhibitory receptor genes with HLA-C and MHC class II alleles in hepatitis C virus infection outcome. Mol. Immunol. 2008, 45:2429-2436.
27. Khakoo S.I., Thio C.L., Martin M.P., Brooks C.R., Gao X., Astemborski J., Cheng J., Goedert J.J., Vlahov D., Hilgartner M., Cox S., Little A.M., Alexander G.J., Cramp M.E., O'Brien S.J., Rosenberg W.M., Thomas D.L., Carrington M. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004, 305:872-874.
28. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2001, 34:1225-1241.
29. Bunce M., O'Neill C.M., Barnardo M.C., Krausa P., Browning M.J., Morris P.J., Welsh K.I. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995, 46:355-367.
30. Martin M.P., Nelson G., Lee J.H., Pellett F., Gao X., Wade J., Wilson M.J., Trowsdale J., Gladman D., Carrington M. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J. Immunol. 2002, 169:2818-2822.
31. Witt C.S., Dewing C., Sayer D.C., Uhrberg M., Parham P., Christiansen F.T. Population frequencies and putative haplotypes of the killer cell immunoglobulin-like receptor sequences and evidence for recombination. Transplantation 1999, 68:1784-1789.
32. Alter G., Martin M.P., Teigen N., Carr W.H., Suscovich T.J., Schneidewind A., Streeck H., Waring M., Meier A., Brander C., Lifson J.D., Allen T.M., Carrington M., Altfeld M. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J. Exp. Med. 2007, 204:3027-3036.
33. Boyington J.C., Brooks A.G., Sun P.D. Structure of killer cell immunoglobulin-like receptors and their recognition of the class I MHC molecules. Immunol. Rev. 2001, 181:66-78.
34. Uhrberg M., Parham P., Wernet P. Definition of gene content for nine common group B haplotypes of the Caucasoid population: KIR haplotypes contain between seven and eleven KIR genes. Immunogenetics 2002, 54:221-229.
35. Yawata M., Yawata N., McQueen K.L., Cheng N.W., Guethlein L.A., Rajalingam R., Shilling H.G., Parham P. Predominance of group A KIR haplotypes in Japanese associated with diverse NK cell repertoires of KIR expression. Immunogenetics 2002, 54:543-550.
36. Niokou D., Spyropoulou-Vlachou M., Darlamitsou A., Stavropoulos-Giokas C. Distribution of killer cell immunoglobulin-like receptors in the Greek population. Hum. Immunol. 2003, 64:1167-1176.
37. Wu G.Q., Zhao Y.M., Lai X.Y., Yang K.L., Zhu F.M., Zhang W., Wang W., Luo Y., Tan Y.M., Wang Y.J., Cao W.J., Huang H. Distribution of killer-cell immunoglobulin-like receptor genes in Eastern mainland Chinese Han and Taiwanese Han populations. Tissue Antigens 2009, 74:499-507.
38. Uhrberg M. The KIR gene family: life in the fast lane of evolution. Eur. J. Immunol. 2005, 35:10-15.
39. Levinson R.D., Du Z., Luo L., Holland G.N., Rao N.A., Reed E.F., Rajalingam R. KIR and HLA gene combinations in Vogt-Koyanagi-Harada disease. Hum. Immunol. 2008, 69:349-353.
40. Zuniga J., Romero V., Azocar J., Terreros D., Vargas-Rojas M.I., Torres-Garcia D., Jimenez-Alvarez L., Vargas-Alarcon G., Granados-Montiel J., Husain Z., Chung R.T., Alper C.A., Yunis E.J. Protective KIR-HLA interactions for HCV infection in intravenous drug users. Mol. Immunol. 2009, 46:2723-2727.
41. Winter C.C., Gumperz J.E., Parham P., Long E.O., Wagtmann N. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J. Immunol. 1998, 161:571-577.
42. Parham P. Immunology. NK cells lose their inhibition. Science 2004, 305:786-787.
43. Guidotti L.G., Rochford R., Chung J., Shapiro M., Purcell R., Chisari F.V. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999, 284:825-829.
44. Biron C.A. Activation and function of natural killer cell responses during viral infections. Curr. Opin. Immunol. 1997, 9:24-34.
45. Tan A.T., Koh S., Goh V., Bertoletti A. Understanding the immunopathogenesis of chronic hepatitis B virus: an Asian prospective. J. Gastroenterol. Hepatol. 2008, 23:833-843.
46. Menne S., Roneker C.A., Roggendorf M., Gerin J.L., Cote P.J., Tennant B.C. Deficiencies in the acute-phase cell-mediated immune response to viral antigens are associated with development of chronic woodchuck hepatitis virus infection following neonatal inoculation. J. Virol. 2002, 76:1769-1780.
47. Chen Y., Wei H., Gao B., Hu Z., Zheng S., Tian Z. Activation and function of hepatic NK cells in hepatitis B infection: an underinvestigated innate immune response. J. Viral. Hepat. 2005, 12:38-45.
48. Boni C., Fisicaro P., Valdatta C., Amadei B., Di Vincenzo P., Giuberti T., Laccabue D., Zerbini A., Cavalli A., Missale G., Bertoletti A., Ferrari C. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 2007, 81:4215-4225.
49. Moretta L., Bottino C., Pende D., Vitale M., Mingari M.C., Moretta A. Different checkpoints in human NK-cell activation. Trends Immunol. 2004, 25:670-676.
50. Tortorella D., Gewurz B.E., Furman M.H., Schust D.J., Ploegh H.L. Viral subversion of the immune system. Annu. Rev. Immunol. 2000, 18:861-926.
51. Martin M.P., Gao X., Lee J.H., Nelson G.W., Detels R., Goedert J.J., Buchbinder S., Hoots K., Vlahov D., Trowsdale J., Wilson M., O'Brien S.J., Carrington M. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 2002, 31:429-434.
52. Carrington M., Wang S., Martin M.P., Gao X., Schiffman M., Cheng J., Herrero R., Rodriguez A.C., Kurman R., Mortel R., Schwartz P., Glass A., Hildesheim A. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J. Exp. Med. 2005, 201:1069-1075.
53. Rehermann B., Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 2005, 5:215-229.